HAT diagnosis relies on laboratory techniques because clinical signs and symptoms are unspecific. Serodiagnostic tests exist only for Tbg and are based on the detection of specific antibodies, thus they are not confirmatory of infection. With the current low disease prevalence, the positive predicti...ve value of serological tests is particularly low. Field-applicable tools include the card agglutination test for trypanosomiasis (CATT) used mainly in active screening by specialized mobile teams, and the rapid diagnostic tests that are more suitable for individual testing at point-of-care.
more
Trachoma is the world’s leading infectious cause of blindness. It is one of 18 neglected
tropical diseases (NTDs) that affect over one billion of the world’s poorest people.
Este folleto presenta los datos sobre la mortalidad por ENT y la prevalencia de factores de riesgo de las ENT, para los países en la región de las Américas. Su contenido está enfocado en la agenda 5 x 5 de ENT que incluye las principals ENT (enfermedades cardiovasculares, cáncer, diabetes y enf...ermedades respiratorias crónicas) y la salud mental (suicidio); así como los principales factores de riesgo de ENT (consumo de tabaco, uso no civo del alcohol, dieta p oco s aludable, ac tividad física insuficiente) junto con la contaminación del aire. Incluye información sobre el número y porcentaje de muertes, tasas de mortalidad estandarizadas por edad, muerte prematura por ENT y la prevalencia de los principales factores de riesgo de las ENT.
more
23 Dec 2020. The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, based on the experience in the EU from August–December, 2020. This document also addresses transmissio...n to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing and the efficacy of partial and full school closures. This document draws upon and updates evidence presented in the previous report from ECDC on this topic, which was published on August 6, 2020
more
This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm...ent in ACT-Accelerator is the world’s best bet and most viable solution for restarting the global economy. It is intended for governments, multilaterals, civil society, businesses and foundations and all those interested in the work required to change the course of the pandemic. The global deployment of ACT-Accelerator’s comprehensive package of tools will reduce the severity of COVID-19 disease, enabling countries to transition out of the crisis thereby restarting domestic and international economic engines driving our global economy.
more
Strategic communication is at the heart of public health and more important than ever in the digital age. Using communication strategically requires expertise, skills and resources to plan, implement and evaluate interventions that encourage governments to implement policies that improve people’s ...lives and well-being, that empower health workers to deliver the best care possible, and that encourage people to take actions that protect and improve their health and that of their family and community. This Regional Action Framework on Communication for Health (C4H) aims to support Member States in implementing the C4H approach. It outlines steps to be taken by WHO and Member States to use C4H to achieve shared public health goals in the Western Pacific.
more
From raising awareness to building capacity
Meeting Report
World Health Organization, Geneva, Switzerland 16 -18 September 2013
DHS Working Papers No. 103
Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries (LMIC). The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in LMIC. Barriers at the... patient, health-care provider, and health system level prevent the implementation of optimal primary and secondary prevention. Identification of the particular barriers that exist in resource-constrained settings is necessary to inform effective strategies to reduce the identified evidence-practice gaps. Furthermore, targeting modifiable factors that contribute most significantly to the global burden of CVD, including tobacco use, hypertension, and secondary prevention for CVD will lead to the biggest gains in mortality reduction. We review a select number of novel, resource-efficient strategies to reduce premature mortality from CVD, including: (1) effective measures for tobacco control; (2) implementation of simplified screening and management algorithms for those with or at risk of CVD, (3) increasing the availability and affordability of simplified and cost-effective treatment regimens including combination CVD preventive drug therapy, and (4) simplified delivery of health care through task-sharing (non-physician health workers) and optimizing self-management (treatment supporters). Developing and deploying systems of care that address barriers related to the above, will lead to substantial reductions in CVD and related mortality.
more
Concentrations of the major greenhouse gases, CO2 , CH4 , and N2 O, continued to increase despite the temporary reduction in emissions in 2020 related to measures taken in response to COVID-19.
2020 was one of the three warmest years on record. The past six years, including 2020, have been the si...x warmest years on record. Temperatures reached 38.0 °C at Verkhoyansk, Russian Federation on 20 June, the highest recorded temperature anywhere north of the Arctic Circle.
The trend in sea-level rise is accelerating. In addition, ocean heat storage and acidification are increasing, diminishing the ocean’s capacity to moderate climate change.
more
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.